Oral phosphate-binding medications are necessary to treat hyperphosphatemia, a condition that occurs in nearly all individuals who receive dialysis treatments. If not treated, hyperphosphatemia can increase mortality, vascular calcification, and cardiovascular events. Currently, patients can access these drugs at their local pharmacy, but as of January 1, 2025, a new policy change from the Centers for Medicare & Medicaid Services (CMS) will instead require dialysis providers to distribute these medications. K is concerned this policy may negatively impact patient access to care, as many dialysis providers lack sufficient infrastructure needed to dispense and ister these drugs.
“We thank Senators Luján and Blackburn for introducing this bill to ensure continued patient access to these vital medications. Without action, CMS’ policy creates yet another challenge for the kidney community to face. Already limited access to innovative treatments and inadequate reimbursement levels are impacting kidney care,” said Colin Roskey, Executive Director of K. “To maintain quality, accessible treatment for individuals living with end-stage renal disease, we urge lawmakers to advance this bill without delay.”